Turning Point Therapeutics, Inc. (TPTX)

Turning Point Therapeutics, Inc. (TPTX) — VMCI valuation read

TPTX screens at VMCI 47/100, a 3-point gap below the Healthcare sector median (50). For a mid-cap Turning Point Therapeutics, Inc. share, that placement says the multi-pillar composite is richer or lower quality than the typical peer on a like-for-like basis.

TPTX has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: TPTX trades at 22.0x earnings, 22% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 16.0% sits 6.0pp above the Healthcare median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 0.6x leaves covenant headroom, which sets the rate-cycle exposure for Turning Point Therapeutics, Inc..

TPTX fell 1.6% over the trailing 7 days, with a -9.4% read on a 30-day basis.